Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
3.55 p
0.24 p(5.04%)
At close: 4:00 PM EST
3.55 p
0.24 p(5.04%)
Day’s Range― - ―
52-Week Range2.50 p - 9.00 p
Previous CloseN/A
Volume846.29K
Average Volume (3M)1.12M
Market Cap
£54.29M
Enterprise Value33.54M
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Target‑engagement SignalA robust pharmacodynamic signal in a controlled LPS human challenge (85%–95% cytokine suppression) provides durable proof‑of‑mechanism evidence. This de‑risks the modality, supports translational rationale for CRS prevention and strengthens negotiating leverage with partners and payers ahead of clinical readouts.
Regulatory & IP ProtectionOrphan designation plus a broad patent family extending to 2044 create structural exclusivity and regulatory incentives. These protections improve long‑term commercial economics, raise barriers to entry, and materially enhance the firm's bargaining position with potential partners and acquirers once clinical efficacy is established.
No Debt And Funded Near‑term RunwayA debt‑free balance sheet with recent fundraising and a material grant provides durable near‑term financial flexibility to execute key clinical milestones (including the summer 2026 interim readout). This reduces immediate refinancing pressure and increases the probability of reaching pivotal value inflection points before larger raises.
Bears Say
Pre‑revenue With Sustained Net LossesPoolbeg remains entirely pre‑revenue with multi‑year operating losses. Persistent negative profitability erodes equity, limits internal funding capacity and means long‑term value creation depends on successful clinical development, partnerships or eventual product sales — structural constraints until commercialization.
Negative Operating Cash Flow & Cash BurnSustained negative operating cash flow and recurring negative free cash flow demonstrate ongoing cash consumption to fund R&D. Even with runway into 2027, the structural need for external capital to fund later‑stage trials increases dilution and execution risk, making long‑term plans contingent on successful funding or licensing.
Dependence On External PartnersReliance on third‑party partners for late‑stage development and commercialization shifts critical execution and commercial outcomes off the company's balance sheet. Partner interest, timing and deal economics materially influence ultimate returns, reducing control over development timelines and long‑term value capture.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.50 p and its highest was 9.00 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £54.29M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 90 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
-55.47%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---